Clinical Trial Update: A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

View source ↗

Summary

A completed study update based on a Spanish medical-record review of adults with relapsed or refractory CD30+ malignancies who were re-treated with Brentuximab …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Takeda | Conditions: Hodgkin Disease, Lymphoma, T-Cell, Cutaneous | Status: COMPLETED